Why the study?
Although use of the direct oral anticoagulant dabigatran has increased, its potential side effects on bone healing and remodeling have not been fully investigated.
Does dabigatran affect early bone healing in male Wistar rats with calvarial bone defects?
Does dabigatran affect early bone healing in male Wistar rats with calvarial bone defects?
Systematic delivery of dabigatran did not impair early bone regeneration in a rat calvarial defect model, suggesting a favorable bone safety profile compared to older anticoagulants like warfarin.
Dabigatran may affect early bone healing in rats; leaves open any clinical impact on human fracture repair or implants.
Background: Dabigatran belongs to the new generation of direct oral anticoagulants (DOACs). Its advantages are oral administration and no need for international normalized ratio (INR) monitoring. Although its use has increased, its potential side effects on bone healing and remodeling have not been fully investigated. The present study aimed to evaluate the possible effects of dabigatran on early bone healing. Methods: Sixteen male Wistar rats were divided into two groups; in group A, 20-mg/kg dabigatran dose was administered orally daily for 15 days, while group B served as a control. Two circular bone defects (d=6 mm) were created on either side of the parietal bones. Two weeks after surgery and euthanasia of the animals, tissue samples (parietal bones that contained the defects) were harvested for histological and histomorphometric analysis. Statistical analysis was performed with a significance level of α=0.5. Results: =0.401). Conclusion: Dabigatran did not affect bone regeneration, suggesting that it might be a safer drug compared to older anticoagulants known to lead to bone healing delay.
No takes yet. Share an insight, caveat, or question.
Kyriakaki et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: